Clinical trial
A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
NCT04987671 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- August 5, 2021
- Completion date
- September 30, 2023
- Enrollment
- 14 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
als